Skip to main content
PVLA logo

Palvella Therapeutics, Inc.

PVLANASDAQHealthcareBiotechnology

$126.23Today:- (-)1Y +77.27%

As of Oct 26, 2026 close

Market cap
$1.81B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$68.96$161.38
Volume (live)
-
Avg. volume (3M)
231.29K

Palvella Therapeutics (PVLA) Cash Flow Statement

In fiscal 2025 (fiscal year ended Mar 31, 2026), Palvella Therapeutics used $25.01M of cash in operating activities. Free cash flow was −$25.01M.

Palvella Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Palvella Therapeutics, Inc. (PVLA) - Annual data in millions USD
BreakdownFY 2025FY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2016
Period endingMar 2026Dec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2016
Operating Activities
Net Income-41.72-41.72-17.43-17.4318.69-33.28-45.74-37.23-25.47-26.75-22.80
Depreciation & Amortization0.00-0.00-0.002.782.372.131.040.570.36
Deferred Income Tax0.00-0.00-0.000.000.000.16-1.22-0.16-
Stock Based Compensation6.406.400.830.830.600.430.000.005.374.941.91
Change in Working Capital3.823.82-0.19-0.19-3.151.6230.53-16.38-32.1221.89-
Change in Accounts Receivable2.492.49-1.98-1.980.00-2.62-1.815.34-4.0612.51-0.06
Change in Inventory0.00-0.00-0.000.000.000.00-0.800.00-
Change in Accounts Payable1.261.262.242.24-2.25-4.217.05-4.351.260.761.36
Change in Other Working Capital0.065.88-0.453.35-29.36-2.3525.29-17.37-28.528.62-1.02
Other Operating Activities6.495.885.963.35-29.36-0.475.195.42-0.07-1.550.05
Net Cash from Operating Activities-25.01-25.01-10.84-10.84-13.70-14.84-7.66-45.90-52.47-1.07-14.39
Investing Activities
Capital Expenditures0.00-0.00-0.00-1.04-0.95-2.73-2.46-1.70-0.58
Acquisitions0.00-0.00-0.000.000.000.00-12.300.00-
Purchases of Investments0.00-0.00-0.000.000.00-41.50-59.32-117.58-
Sales/Maturities of Investments0.00-0.00-0.0028.200.0083.4471.62110.41-
Other Investing Activities0.00-0.00-0.000.000.000.0012.30-7.18-
Net Cash from Investing Activities0.00-0.00-0.00-21.24-0.9539.219.84-8.88-0.56
Financing Activities
Debt Repayment0.00-78.43-0.000.000.000.000.000.00-
Common Stock Issued0.760.760.0060.000.007.2159.1310.1231.0047.21-
Other Financing Activities-1.42-1.428.668.665.009.570.000.001.171.3015.22
Net Cash from Financing Activities-0.66-0.6687.0987.095.009.5759.1310.1232.1748.5115.22
Summary
Effect of Forex Changes on Cash0.050.050.000.000.000.00-3.194.75-2.14-1.58-
Net Change in Cash-25.62-25.6276.2576.25-8.70-5.2747.338.18-12.6136.996.40
Cash at Beginning of Period83.6083.607.357.3516.0521.3370.4462.2674.8737.88-
Cash at End of Period57.9857.9883.6083.607.3516.05117.7670.4462.2674.87-
Free Cash Flow-25.01-25.01-10.84-10.84-13.70-60.97-8.61-48.62-54.93-2.76-14.97

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Palvella Therapeutics Cash Flow

What is Palvella Therapeutics's free cash flow?

Palvella Therapeutics had negative free cash flow of $25.01M in fiscal 2025 (fiscal year ended Mar 31, 2026).

Does Palvella Therapeutics pay dividends or buy back shares?

Palvella Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition